Single-agent gemcitabine in the treatment of advanced breast cancer Journal Article
| Authors: | Modi, S.; Seidman, A. D. |
| Article Title: | Single-agent gemcitabine in the treatment of advanced breast cancer |
| Abstract: | Despite the availability of a number of active cytotoxic agents and combination regimens derived from them, the median survival of patients with metastatic breast cancer (MBC) has not been dramatically prolonged and it remains largely an incurable disease. As such, common goals of treatment in this setting are to ameliorate cancer-related symptoms and maintain or improve patient quality of life for as long as possible. Achieving optimal palliation, however, requires balancing the toxicities of therapy with the cancer-controlling benefits, and, to this end, the development of effective and well-tolerated regimens is a priority. Gemcitabine, a novel nucleoside analogue with demonstrated antitumor activity and a favorable safety profile, has been evaluated in a number of recent clinical trials as single-agent therapy for MBC, including studies of first- and second-line therapy, as well as the salvage setting for patients with taxane- and anthracycline-refractory advanced disease. |
| Keywords: | adult; cancer survival; treatment outcome; aged; clinical feature; clinical trial; drug tolerability; neutropenia; salvage therapy; cytotoxic agent; fluorouracil; diarrhea; dose response; drug efficacy; drug safety; monotherapy; liver dysfunction; capecitabine; gemcitabine; cytarabine; methotrexate; quality of life; drug eruption; infection; breast cancer; anemia; bone marrow suppression; antimetabolites, antineoplastic; lung disease; nausea; stomatitis; thrombocytopenia; vomiting; palliative therapy; cyclophosphamide; antineoplastic activity; breast neoplasms; docetaxel; febrile neutropenia; fever; disease severity; drug mechanism; neoplasm metastasis; flu like syndrome; drug bioavailability; metastasis potential; taxane derivative; drug half life; combination therapy; trastuzumab; navelbine; anthracycline; hand foot syndrome; anthracyclines; deoxycytidine; alopecia; neurologic disease; hypersensitivity reaction; hematologic disease; taxanes; clinical trials, phase ii; clinical trials, phase i; nucleoside derivative; humans; human; female; article |
| Journal Title: | Clinical Breast Cancer |
| Volume: | 4 |
| Issue: | Suppl.3 |
| ISSN: | 1526-8209 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2004-01-01 |
| Start Page: | S101 |
| End Page: | S106 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 14754466 |
| DOI: | 10.3816/CBC.2004.s.002 |
| DOI/URL: | |
| Notes: | Clin. Breast Cancer -- Cited By (since 1996):9 -- Export Date: 16 June 2014 -- CODEN: CBCLB C2 - 14754466 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work